TIDMSLN
RNS Number : 6230T
Silence Therapeutics PLC
16 October 2017
Appointment of Dr. Annalisa Jenkins, MBBS, FRCP as Non-Executive
Chair
16(th) October 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, today announced the appointment of Dr. Annalisa
Jenkins, MBBS, FRCP, CEO of Dimension Therapeutics, Inc.
(NASDAQ:DMTX), as Chair of Silence's Board of Directors. Her
appointment as Non-Executive Chair is effective 16(th) October,
2017, on which date Dr. Stephen Parker, the Company's Non-Executive
Chairman since September 2015 will become a Non-Executive
Director.
A biopharma thought leader, Dr. Jenkins brings over 25 years of
global industry experience to Silence's Board with a wealth of
knowledge in advancing programs from scientific research through
clinical development, regulatory approval and into healthcare
systems globally. Prior to Dimension, Dr. Jenkins held multiple
leadership positions, including executive vice president, head of
Global Research and Development for Merck Serono. She led Global
Medical Affairs and Quality and was a member of Merck Serono's
Pharmaceutical Executive Committee. Previously, Dr. Jenkins had a
nearly 15-year successful career at Bristol-Myers Squibb (BMS),
attaining the role of senior vice president and head of Global
Medical Affairs. During her tenure at BMS, Dr. Jenkins played a key
role in the development, approval, and/or commercialization of
products in multiple therapeutic areas, including immuno-oncology,
cardiology, immunology and infectious diseases. She began her
career as a medical officer with the British Royal Navy during the
Gulf conflict, rising to the rank of Surgeon Lieutenant Commander.
Dr. Jenkins graduated in medicine from St. Bartholomew's Hospital,
London, and trained in cardiovascular medicine in the UK National
Health Service.
In addition to the current and past Directorships listed below,
Dr. Jenkins is also a committee member of the Science Board to the
FDA, serves on the advisory board of the Center for Talent
Innovation (U.K.) and is on the Advisory Panel of the Healthcare
Businesswomen's Association.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"Annalisa's appointment is a significant moment in the
transition of Silence to a fully-integrated biopharma company. Her
extensive and broad experience in all aspects of biotechnology,
drug development and commercialization will prove to be invaluable.
It is a testament to the progress made at Silence that we have been
able to attract Annalisa to our Board. Her appointment is a signal
of our continued belief that 2017 will be remembered as "the year
of RNAi.""
"At the same time, I would like to thank Dr. Stephen Parker for
his two-year tenure as Chairman. At a very difficult time for the
company and for myself personally, Steve has been instrumental in
steering the company to the position that it is in today. We are
delighted that Steve will remain on the Board as an important
member of the team."
Dr. Annalisa Jenkins commented:
"Given the recent advances in delivery and chemistry in the RNAi
field, I am now of the belief that gene silencing will be a major
new drug modality. I believe that Silence's technology and IP
represent a significant opportunity in the next generation of drugs
that will potentially transform the treatment of serious diseases
with significant unmet medical need, specifically where the liver
is the primary target organ. These disorders often have devastating
outcomes for patients and their families, and I look forward to
contributing to the Company's advancement of these promising
product candidates towards the clinic."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Full name and age: Dr. Annalisa Mary Jenkins (aged 52).
Dr. Jenkins does not currently hold any ordinary shares in
Silence Therapeutics.
Current Directorships or Partnerships:
Annalisa Jenkins LLC
Ardelyx, Inc.
Cocoon Biotech Inc.
Dimension Therapeutics, Inc.
iOX Therapeutics Limited
MedCity Limited
OncoSec Medical Incorporated
The Olivia Rose Fund
Thrombolytic Science, LLC
Vium, Inc.
YouBelong
Previous Directorships or Partnerships:
Ares Trading SA
Biothera Pharmaceuticals, Inc.
Prosensa Holding N.V.
TransCelerate BioPharma Inc.
Viventia Bio, Inc.
No further information in connection with her appointment is
required to be disclosed under Schedule Two, paragraph (g) of the
Aim Rules for Companies.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20
and Broker) 7418 8900
James Steel/Oliver Jackson
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALIFEAIILELID
(END) Dow Jones Newswires
October 16, 2017 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024